Skip to main content
SpringerLink
Log in
Book cover

Drugs, Systemic Diseases, and the Kidney pp 191–197Cite as

Selected Aspects of Drug use in Renal Failure

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 252))

Abstract

The kidney is the major organ involved in the elimination of drugs and their pharmacologically active metabolites. Thus, the frequency and severity of adverse drug reactions are increased in patients with renal insufficiency. Updated recommendations for the use of relevant drugs in patients with varying degrees of renal dysfunction are available (1–3). This paper will review selected aspects of this large subject, emphasizing topics of recent interest and for which new information is available.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. W.M. Bennett, G.R. Aronoff, T.A. Golper, G. Morrison, I. Singer, and D.C. Brater, “Drug Prescribing in Renal Failure: Dosing Guidelines for Adults,” American College of Physicians, Philadelphia (1987).

    Google Scholar 

  2. W.E. Reed and S. Sabatini, The use of drugs in renal failure. Seminars in Nephrology 6:259–295 (1986).

    PubMed  CAS  Google Scholar 

  3. D.C. Brater, “Drug Use in Clinical Medicine,” B.C. Decker, Toronto (1987).

    Google Scholar 

  4. R.J. Osborne, S.P. Joel, and M.L. Slevin, Morphine intoxication in renal failure: role of morphine-6-glucuronide, Br Med J 292:1548–1549 (1986).

    Article  CAS  Google Scholar 

  5. J. Sawe, and I. Odar-Cederlof, Kinetics of morphine in patients with renal failure, Eur J Clin Pharmacol 32:377–382 (1987).

    Article  PubMed  CAS  Google Scholar 

  6. G.R. Park, M.P. Shelly, A.R. Manara, and K. Quinn, Sedation in intensive care: morphine and renal failure. Intensive Care Med 13:365–366 (1987).

    PubMed  CAS  Google Scholar 

  7. D.F. Woolner, D. Winter, T.J. Frendin, E.J. Begg, K.L. Lemn, and G.J. Wright, Renal failure does not impair the metabolism of morphine, Br J Clin Pharmacol 22:55–59 (1986).

    Article  PubMed  CAS  Google Scholar 

  8. P.J. Ratcliffe, J.W. Sear, QMJ, Hand, and R.A. Moore, Morphine transport in the isolated perfused rat kidney, Proc EDTA-ERA 22:1109–1114 (1985).

    Google Scholar 

  9. G.L. Chan, G. Matzke, Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opiod analgesics, Drug Intell Clin Pharm 21:773–783 (1937).

    Google Scholar 

  10. K Chan, J Tse, F Jennings, and M. Orme, Pharmacokinetics of low dose intravenous pethidine in patients with renal dysfunction, J Clin Pharmacol 27:516–522 (1987).

    PubMed  CAS  Google Scholar 

  11. W.M. Bennett, M.N. Hartnett, R. Craven, D.N. Gilbert, and G.A. Porter, Gentamicin concentrations in blood, urine and renal tissue of patients with end-stage renal disease, J Lab Clin Med 30:389–394 (1977).

    Google Scholar 

  12. W.M. Bennett and R. Craven, Ampicillin and trimethoprim- sulfamethoxazole treatment of urinary tract infections in patients with severe renal disease, JAMA 236:946–950 (1976).

    Article  PubMed  CAS  Google Scholar 

  13. C. Langston, D.A. Roberts, G.A. Porter, and W.M. Bennett, Renal phycomycosis, J Urol 109:941–944 (1973).

    PubMed  CAS  Google Scholar 

  14. R. Huseman, A. Grady, D. Welling, and J. Grantham, Macropuncture study of polycystic disease in adult human kidneys, Kidney Int 18:375–385 (1980).

    Article  PubMed  CAS  Google Scholar 

  15. J.J. Grantham, J.L. Geiser, and A.E. Evan, Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int 31:1145–1152 (1987).

    Article  PubMed  CAS  Google Scholar 

  16. R.S. Muther and W.M. Bennett, Cyst fluid antibiotic concentrations in polycystic kidney disease: differences between proximal and distal cysts. Kidney Int 20:519–522 (1981).

    Article  PubMed  CAS  Google Scholar 

  17. L. Elzinga, T. Golper, A.L. Rashad, M.E. Carr, and W.M. Bennett, Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 32:884–888 (1987).

    Article  PubMed  CAS  Google Scholar 

  18. S.J. Schwab, Efficacy of chloramphenicol in refractory cyst infections in autosomal dominant polycystic kidney disease, Am J Kidney Dis 5:258–261 (1985).

    PubMed  CAS  Google Scholar 

  19. W.M. Bennett, L. Elzinga, J.P. Pulliam, A.L. Rashad, and J.M. Barry, Cyst fluid antibiotic concentrations in autosomal dominant polycystic kidney disease. Am J Kidney Dis 6:400–404 (1985).

    PubMed  CAS  Google Scholar 

  20. S. Schwab, D. Hinthorn, and J.J. Grantham, pH-dependent accumulation of clinamycin in polycystic kidneys. Am J Kidney Pis 3:63–66 (1983).

    CAS  Google Scholar 

  21. W.M. Bennett, T.A. Golper, and L.W. Elzinga, Fluoroquinolones in patients with polycystic kidney disease, Aust NZ J Med (in press).

    Google Scholar 

  22. S.J. Schwab, S.J. Bander, and S. Klahr, Renal infection in autosomal dominant polycystic kidney disease. Am J Med 82:714–718 (1987).

    Article  PubMed  CAS  Google Scholar 

  23. R. Sweet and W. Keane, Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron 23:237–240 (1979).

    Article  PubMed  CAS  Google Scholar 

  24. G.R. Matzke, R.L. Lucarotti, and H.S. Shapiro, Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol 3:11–17 (1983).

    Article  PubMed  CAS  Google Scholar 

  25. W.M. Bennett, G.W. Wood, D.C. Houghton, and D.N. Gilbert, Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 3:292–296 (1986).

    Google Scholar 

  26. W.M. Bennett, G.A. Wood, S.J. Kohlhepp, P.W. Kohnen, D.C. Houghton, and D.N. Gilbert, Experimental gentamicin nephrotoxicity can be prevented by polyaspartic acid, Kidnev Int 33:353 (1988).

    Google Scholar 

  27. G.A. Wood, D.R. Norton, S.J. Kohlhepp, P.W. Kohnen, W.M. Bennett, G.A. Porter, D.C. Houghton, R.E. Brummett, and D.N. Gilbert, The influence of tobramycin dosage regimen on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess, J Infect Dis (in press).

    Google Scholar 

  28. R.W. Bundtzgen, A.U. Gefbër, D.L. Cohen, and W.A. Craig, Postantibiotic suppression of bacterial growth, Rev Infect Pis 3:28–37 (1981).

    Article  Google Scholar 

  29. J. Blaser, B.B. Stone, and S.H. Zinner, Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model, Antimicrob Agents Chemother 27:343–349 (1985).

    Article  PubMed  CAS  Google Scholar 

  30. J. Kapusnik, C. Hackbarth, H. Chambers, K. Scott, T. Carpenter, and M. Sande, Efficacy of once daily versus intermittent dosing of tobramycin in neutropenic and normal, sedated guinea pigs with experimental Pseudomonas pneumonia [Abstract 548], in: Program and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., American Society for Microbiology (1985).

    Google Scholar 

  31. M. Pechere, k. Letarte, and J-C Pechere, Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia, J Antimicrob Chemother 19:487–491 (1987).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland, Oregon, USA

    William M. Bennett & Lawrence W. Elzinga

Authors
  1. William M. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence W. Elzinga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Bari, Bari, Italy

    Alberto Amerio  & Pasquale Coratelli  & 

  2. University of Southern California, Los Angeles, California, USA

    Vito M. Campese  & Shaul G. Massry  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Plenum Press, New York

About this chapter

Cite this chapter

Bennett, W.M., Elzinga, L.W. (1989). Selected Aspects of Drug use in Renal Failure. In: Amerio, A., Coratelli, P., Campese, V.M., Massry, S.G. (eds) Drugs, Systemic Diseases, and the Kidney. Advances in Experimental Medicine and Biology, vol 252. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8953-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-8953-8_19

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-8955-2

  • Online ISBN: 978-1-4684-8953-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation